Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01905592
Title A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)
Acronym BRAVO
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Tesaro, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | NLD | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | CAN | BEL


No variant requirements are available.